Cancer Research Technology
Log in Register
Menu

MCF7A BCAR3 [MCF7-BCAR3] cell line

Invented at Erasmus Medical Center

Info

Catalogue Number 154637
Antigen/Gene or Protein Targets BCAR3
Parental Line MCF7A
Synonyms Breast Cancer Anti-Estrogen Resistance 3; SH2 Domain-Containing Protein 3B; NSP2
Host Human
Tissue Breast
Disease Keywords Mammary adenocarcinoma, estrogen-dependent
Model Cancer Model
Relevance Breast cancer is widely and effectively treated with endocrine treatment. However, in many disease cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype

Seven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in MCF7A human breast cancer cells. This cell line is part of a panel of 4 cell lines (Cat No 154636-154638, 154643) which have been transfected with these genes, plus the parental (Cat No 154546)

These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
Production Details Full length BCAR3 cDNA was introduced in the estrogen-dependent MCF7A cell line by transfection with lipofectamine
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS)
Notes This cell line is also resistant to Geneticin which may be included in the culture to maintain the expression plasmid

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

van Agthoven et al. 1998. EMBO J. 17(10):2799-808. PMID: 9582273.


Add a reference

References: 1 entry

van Agthoven et al. 1998. EMBO J. 17(10):2799-808. PMID: 9582273.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor